BR112021007414A2 - ativadores cliváveis de cxcr3 e métodos de uso - Google Patents

ativadores cliváveis de cxcr3 e métodos de uso Download PDF

Info

Publication number
BR112021007414A2
BR112021007414A2 BR112021007414-7A BR112021007414A BR112021007414A2 BR 112021007414 A2 BR112021007414 A2 BR 112021007414A2 BR 112021007414 A BR112021007414 A BR 112021007414A BR 112021007414 A2 BR112021007414 A2 BR 112021007414A2
Authority
BR
Brazil
Prior art keywords
peptide
cxcl
amino acid
recombinant
seq
Prior art date
Application number
BR112021007414-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Alan H. Wells
Original Assignee
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Pittsburgh - Of The Commonwealth System Of Higher Education filed Critical University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Publication of BR112021007414A2 publication Critical patent/BR112021007414A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112021007414-7A 2018-10-22 2019-10-18 ativadores cliváveis de cxcr3 e métodos de uso BR112021007414A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748711P 2018-10-22 2018-10-22
US62/748,711 2018-10-22
PCT/US2019/056955 WO2020086400A1 (en) 2018-10-22 2019-10-18 Cleavable activators of cxcr3 and methods of use

Publications (1)

Publication Number Publication Date
BR112021007414A2 true BR112021007414A2 (pt) 2021-08-10

Family

ID=70330587

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021007414-7A BR112021007414A2 (pt) 2018-10-22 2019-10-18 ativadores cliváveis de cxcr3 e métodos de uso

Country Status (12)

Country Link
US (2) US12110316B2 (https=)
EP (1) EP3870212A4 (https=)
JP (3) JP7426121B2 (https=)
KR (1) KR20210081372A (https=)
CN (2) CN120022352A (https=)
AU (2) AU2019365654B2 (https=)
BR (1) BR112021007414A2 (https=)
CA (1) CA3116325A1 (https=)
IL (2) IL324815A (https=)
MX (1) MX2021004496A (https=)
SG (1) SG11202103497WA (https=)
WO (1) WO2020086400A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210081372A (ko) * 2018-10-22 2021-07-01 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 절단 가능한 cxcr3의 활성제 및 이의 사용 방법
GB202208950D0 (en) * 2022-06-17 2022-08-10 Ucl Business Ltd Treatment of the corneal endothelium
WO2024118744A2 (en) * 2022-11-30 2024-06-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Coacervate formulations of cxcr3-activating peptides for controlled release in ophthalmic and topical treatments

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
MXPA00003885A (es) 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US20070116669A1 (en) * 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
GB2377444A (en) 2001-04-09 2003-01-15 Smithkline Beecham Plc Chemokine-family polypeptide
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
US9180167B2 (en) 2011-08-26 2015-11-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Activators of CXCR3 for the treatment of angiopathies of the eye
US8734775B2 (en) 2011-08-26 2014-05-27 University Of Pittsburgh Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
AU2014306074B2 (en) * 2013-08-05 2018-08-30 Greenlight Biosciences, Inc. Engineered proteins with a protease cleavage site
US9895419B2 (en) * 2014-01-21 2018-02-20 University of Pittsburgh—of the Commonwealth System of Higher Education Goblet cell replacement therapy
ES2738582T3 (es) * 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
AU2017290828A1 (en) * 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20210081372A (ko) 2018-10-22 2021-07-01 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 절단 가능한 cxcr3의 활성제 및 이의 사용 방법

Also Published As

Publication number Publication date
EP3870212A1 (en) 2021-09-01
SG11202103497WA (en) 2021-05-28
JP2022512770A (ja) 2022-02-07
US20250002549A1 (en) 2025-01-02
US20210388048A1 (en) 2021-12-16
JP2025172140A (ja) 2025-11-20
IL282431A (en) 2021-06-30
EP3870212A4 (en) 2022-11-16
AU2019365654A1 (en) 2021-05-13
JP7798368B2 (ja) 2026-01-14
CN113038965A (zh) 2021-06-25
IL324815A (en) 2026-01-01
IL282431B2 (en) 2026-04-01
AU2019365654A8 (en) 2021-05-20
WO2020086400A1 (en) 2020-04-30
CN120022352A (zh) 2025-05-23
US12110316B2 (en) 2024-10-08
KR20210081372A (ko) 2021-07-01
JP2024009210A (ja) 2024-01-19
CN113038965B (zh) 2025-02-07
JP7426121B2 (ja) 2024-02-01
AU2025200880A1 (en) 2025-03-06
AU2019365654B2 (en) 2024-11-14
IL282431B1 (en) 2025-12-01
MX2021004496A (es) 2021-06-04
CA3116325A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US20250002549A1 (en) Cleavable activators of cxcr3 and methods of use
JP7725540B2 (ja) 眼の感染症および疾患を処置するための組成物および方法
JP7117012B2 (ja) 糖尿病網膜症を予防または治療するための方法
CN102827253B (zh) 一种抑制炎症反应的小分子多肽及其应用
US20210386837A1 (en) Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
JP7194440B2 (ja) 心臓病変を改善するための方法
JP7455457B2 (ja) 筋萎縮性側索硬化症を治療するための方法と薬剤
US20100150872A1 (en) Polypeptides derived from the hemopexin-like domain of metalloproteinase mmp-2
KR20230005298A (ko) 척수성 근위축증의 치료 방법 및 약물
HK40123732A (zh) Cxcr3的可切割激活剂及其使用方法
CN111905103A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
HK40055610B (zh) Cxcr3的可切割激活剂及其使用方法
CN103897034B (zh) 一种预防和/或治疗炎症反应的小分子多肽及其应用
HK40055610A (en) Cleavable activator of cxcr3 and use method thereof
US9896488B2 (en) Protamine in treatment of neuronal injuries
CN104004066B (zh) 预防或抑制炎症反应和血管新生的小分子多肽及其应用
HK1240129A1 (en) Method for preventing or treating diabetic retinopathy
Class et al. Patent application title: PROTAMINE IN TREATMENT OF NEURONAL INJURIES
Qi et al. Tissue Inhibitor of Metalloproteinases-3 Peptides Inhibit Angiogenesis and Choroidal
HK1240124A1 (en) Method for preventing or treating diabetic nerve injury and related diseases

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]